Article Text

other Versions

PDF
Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case control study
  1. Debby Vosse (d.vosse{at}mumc.nl)
  1. Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Netherlands
    1. Robert Landewé
    1. Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Netherlands
      1. Desirée van der Heijde (d.vanderheijde{at}kpnplanet.nl)
      1. Leiden University Medical Center, Netherlands
        1. Sjef van der Linden
        1. Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Netherlands
          1. Tjeerd-Pieter van Staa
          1. Medical Research Council Epidemiology Resource Centre and Centre for Developmental Origins of Healt, United Kingdom
            1. Piet Geusens
            1. Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Netherlands

              Abstract

              Background and Aims: Ankylosing spondylitis (AS) is associated with bone loss in the vertebrae and an increased prevalence of vertebral fractures, but literature about the magnitude of the risk of fracturing is limited. One retrospective cohort study provided evidence of an increased risk of clinical vertebral fractures but not for non-vertebral fractures. This study further explores the risk of clinical vertebral and non-vertebral fractures in a large population database.

              Methods: In a primary care-based nested case-control study, 231,778 fracture cases and 231,778 age- and sex-matched controls were recruited. A history of AS was assessed from the medical records. AS was diagnosed in a total of 758 people. Odds ratios (OR) and 95% confidence intervals (CI) were calculated after adjustment for medication, other illnesses, smoking and body mass index whenever known.

              Results: The prevalence of AS was 0.18% in fracture cases and 0.15% in controls. Patients with AS had an increased risk of clinical vertebral fracture (OR: 3.26; CI: 1.51-7.02). The risk for forearm and hip fracture was not significantly increased (OR: 1.21 [CI: 0.87-1.69] and 0.77 [CI: 0.43-1.37], respectively). The risk of any clinical fracture was increased in AS patients with a history of inflammatory bowel disease (IBD) (OR: 2.79, CI: 1.10-7.08), whereas it was decreased in AS patients taking non-steroidal anti-inflammatory drugs (NSAID’s) (OR: 0.65, CI: 0.50-0.84). The risk was not associated with recent back pain, psoriasis, joint replacement therapy and use of sulfasalazine.

              Conclusions: Patients with AS have an increased risk of clinical vertebral fracture, but not of non-vertebral fractures, while in patients with concomitant IBD the risk of any clinical fracture is increased. The mechanism by which intake of NSAID’s reduces the risk of any clinical fracture warrants further research.

              Statistics from Altmetric.com

              Request permissions

              If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.